Genetic predisposition of six well-defined polymorphisms in HMGB1/RAGE pathway to breast cancer in a large Han Chinese population

Journal of Cellular and Molecular Medicine

Volumn 20, Issue 10, 2016, Pages 1966-1973

  Yue, Liling ^a   Zhang, Qibing ^b   He, Lan ^a   Zhang, Minglong ^a   Dong, Jing ^a   Zhao, Dalong ^c   Ma, Hongxing ^b   Pan, Hongming ^a   Zheng, Lihong ^a  

^a QIQIHAR MEDICAL UNIVERSITY   (China)

^b DAQING OILFIELD CO LTD   (China)

^c Obstetrics and Gynecology Department   (China)

Author keywords

breast cancer; genetic score; haplotype; HMGB1 RAGE pathway; polymorphism

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MOK PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; CHINA; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCORING SYSTEM; SIGNAL TRANSDUCTION; TUMOR VOLUME; ALLELE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MODEL; BREAST TUMOR; DOMINANT GENE; GENE FREQUENCY; GENE LOCUS; GENETICS; HAPLOTYPE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ANTIGENS, NEOPLASM; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENES, DOMINANT; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HMGB1 PROTEIN; HUMANS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84973640794     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12888     Document Type: Article

References (33)

1. Jia M, Zheng R, Zhang S, et al. Female breast cancer incidence and mortality in 2011, China. J Thorac Dis. 2015; 7: 1221–6.
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66: 115–32.
3. Hemminki K, Granstrom C. Familial breast cancer: scope for more susceptibility genes? Breast Cancer Res Treat. 2003; 82: 17–22.
4. Lynch H, Wen H, Kim YC, et al. Can unknown predisposition in familial breast cancer be family-specific? Breast J. 2013; 19: 520–8.
5. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007; 447: 1087–93.
6. Michailidou K, Beesley J, Lindstrom S, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015; 47: 373–80.
7. Zheng W, Long J, Gao YT, et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet. 2009; 41: 324–8.
8. Chung HW, Lee SG, Kim H, et al. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med. 2009; 7: 38.
9. Sun S, Zhang W, Cui Z, et al. High mobility group box-1 and its clinical value in breast cancer. Onco Targets Ther. 2015; 8: 413–9.
10. Tang D, Kang R, Zeh HJ 3rd, et al. High-mobility group box 1 and cancer. Biochim Biophys Acta. 2010; 1799: 131–40.
11. Dong YD, Cui L, Peng CH, et al. Expression and clinical significance of HMGB1 in human liver cancer: knockdown inhibits tumor growth and metastasis in vitro and in vivo. Oncol Rep. 2013; 29: 87–94.
12. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis. 2008; 11: 91–9.
13. Lotze MT, DeMarco RA. Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs. 2003; 4: 1405–9.
14. Fahmueller YN, Nagel D, Hoffmann RT, et al. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer. 2013; 132: 2349–58.
15. Ladoire S, Penault-Llorca F, Senovilla L, et al. Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. Autophagy. 2015; 11: 1878–90.
16. Stoetzer OJ, Fersching DM, Salat C, et al. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol. 2013; 34: 81–90.
17. Pan H, He L, Wang B, et al. The relationship between RAGE gene four common polymorphisms and breast cancer risk in northeastern Han Chinese. Sci Rep. 2014; 4: 4355.
18. Wang Y, Li XP, Yin JY, et al. Association of HMGB1 and HMGB2 genetic polymorphisms with lung cancer chemotherapy response. Clin Exp Pharmacol Physiol. 2014; 41: 408–15.
19. Feng LJ, Liu HL, Tan Q, et al. 374T/A polymorphism of the receptor for advanced glycation end products is associated with decreased risk of breast cancer in a Chinese population. Int J Clin Exp Med. 2015; 8: 10109–13.
20. Tesarova P, Kalousova M, Jachymova M, et al. Receptor for advanced glycation end products (RAGE)–soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest. 2007; 25: 720–5.
21. Hashemi M, Moazeni-Roodi A, Arbabi F, et al. Genotyping of -374A/T, -429A/G, and 63 bp Ins/del polymorphisms of RAGE by rapid one-step hexaprimer amplification refractory mutation system polymerase chain reaction in breast cancer patients. Nucleos Nucleot Nucl Acids. 2012; 31: 401–10.
22. Niederhauser C, Kaempf L, Heinzer I. Use of the ligase detection reaction-polymerase chain reaction to identify point mutations in extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis. 2000; 19: 477–80.
23. Dupont WD, Plummer WD Jr. Power and sample size calculations for studies involving linear regression. Control Clin Trials. 1998; 19: 589–601.
24. Nasser MW, Wani NA, Ahirwar DK, et al. RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment. Cancer Res. 2015; 75: 974–85.
25. Ke S, Zhou F, Yang H, et al. Downregulation of high mobility group box 1 modulates telomere homeostasis and increases the radiosensitivity of human breast cancer cells. Int J Oncol. 2015; 46: 1051–8.
26. Sharaf H, Matou-Nasri S, Wang Q, et al. Advanced glycation endproducts increase proliferation, migration and invasion of the breast cancer cell line MDA-MB-231. Biochim Biophys Acta. 2015; 1852: 429–41.
27. Ishibashi Y, Matsui T, Takeuchi M, et al. Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase. Horm Metab Res. 2013; 45: 387–90.
28. Amornsupak K, Insawang T, Thuwajit P, et al. Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells. BMC Cancer. 2014; 14: 955.
29. Gurwitz D, Weizman A, Rehavi M. Education: teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends Pharmacol Sci. 2003; 24: 122–5.
30. Sharafeldin N, Slattery ML, Liu Q, et al. A candidate-pathway approach to identify gene-environment interactions: analyses of colon cancer risk and survival. J Natl Cancer Inst. 2015; 107: pii: djv160. doi: 10.1093/jnci/djv160.
31. Teare MD. Candidate gene association studies. Methods Mol Biol. 2011; 713: 105–17.
32. Moore JH, Williams SM. New strategies for identifying gene-gene interactions in hypertension. Ann Med. 2002; 34: 88–95.
33. Galera C, Orriols L, M'Bailara K, et al. Mind wandering and driving: responsibility case-control study. BMJ. 2012; 345: e8105.